Cantor’s Mara Goldstein acknowledges shares have hit some challenges in the latest months, but believes ultimately the company’s programs carry “undiminished” value.
Barclays analyst Jonathan Eckard has boosted the price target for shares of Advaxis, Inc. (NASDAQ:ADXS), from $15 to $20, while reiterating a Buy …
In a research report sent to investors, H.C.